Why Is Ionis Pharma Stock Skyrocketing Tuesday? - Ionis Pharmaceuticals (NASDAQ:IONS)

Ionis drug lowers triglycerides, reduces pancreas damage in late-stage studies

New data on the therapy showed it lowered the triglycerides of patients with a common condition, which may make it a blockbuster medication.

Why Is Ionis Pharma Stock Skyrocketing Tuesday? - Ionis Pharmaceuticals (NASDAQ:IONS)

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) on Tuesday released topline results from the pivotal Phase 3 CORE and CORE2 studies of olezarsen for severe hypertriglyceridemia (sHTG). sHTG is a condition where triglyceride levels are significantly elevated, typically 500 mg/dL or higher, which is a major risk factor for acute pancreatitis. In December 2024, the FDA approved Ionis Pharmaceuticals’ Tryngolza (olezarsen) as an adjunct to diet to reduce …

Touches New High on Promising Olezarsen Results

We recently published 10 Power Stocks Crushing Wall Street — 7 at All-Time Highs. Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is one of the best performers on Tuesday. Ionis Pharmaceuticals soared to a new all-time high on Tuesday, as investors cheered promising results from the phase 3 studies of…

Olezarsen Shows Promising Results in Reducing Triglycerides and Pancreatitis Risk Ionis Pharmaceuticals Reports Key A...

'Olezarsen: A Revolutionary Breakthrough in Treating Hypertriglyceridemia by Ionis Pharmaceuticals' Hypertriglyceridemia (HTG), characterized by elevated levels of triglycerides in the blood, poses a significant health risk for individuals worldwide. Severe hypertriglyceridemia (sHTG) can lead to acute pancreatitis, a condition that causes inflammation of the pancreas and is associated with life-threatening complications if not managed effective…